Georgia's Online Cancer Information Center

Find A Clinical Trial

A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma

Status
Active
Cancer Type
Bone and Soft Tissue (including Sarcoma)
Ewing Sarcoma
Lymphoma
Neuroblastoma
Trial Phase
Phase I
Phase II
Eligibility
6 Months - 21 Years, Male and Female
Study Type
Treatment
NCD ID
NCT03458728
Protocol IDs
19176 (primary)
NCI-2018-00809
2017-000383-15
Study Sponsor
Bayer Corporation

Summary

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.